首页 > 最新文献

American Journal of Hematology最新文献

英文 中文
Clinician Assessment for Acute Chest Syndrome in Febrile Children With Sickle Cell Disease Revisited. 镰状细胞病发热患儿急性胸综合征的临床评价
IF 12.8 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-29 DOI: 10.1002/ajh.70213
Dunia Hatabah,Noor Alzraikat,Zayir M Malik,Sarah G Lazarus,Rawan Korman,Nitya Bakshi,Chris A Rees,Robert Hagbom,Claudia R Morris
{"title":"Clinician Assessment for Acute Chest Syndrome in Febrile Children With Sickle Cell Disease Revisited.","authors":"Dunia Hatabah,Noor Alzraikat,Zayir M Malik,Sarah G Lazarus,Rawan Korman,Nitya Bakshi,Chris A Rees,Robert Hagbom,Claudia R Morris","doi":"10.1002/ajh.70213","DOIUrl":"https://doi.org/10.1002/ajh.70213","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"73 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146069957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vascular Geometry Drives Stroke Risk in Sickle Cell Disease 血管几何驱动镰状细胞病卒中风险。
IF 9.9 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-28 DOI: 10.1002/ajh.70184
Weiqiang Liu, Christian Kassasseya, Lazaros Papamanolis, Kim-Anh Nguyen-Peyre, Morgane Garreau, Saskia Eckert, Gonzalo De Luna, Thomas d'Humières, Vincent de Pierrefeu, Cecile Arnaud, Nour Bekeziz, Marie Pierre Gobin Metteil, Corentin Provost, Jean-Frédéric Gerbeau, Suzanne Verlhac, Pablo Bartolucci, Irene Vignon-Clementel

Sickle cell disease (SCD) is the leading cause of stroke in children and young adults, primarily due to cerebral vasculopathy (CV) occurring within the first decade of life. The main risk factor for CV is elevated blood velocity in intracranial arteries, contributing to stenosis formation in very young children. This study addresses three key questions: (i) the relationship between hemoglobin levels and intracranial blood velocities in SCD patients, (ii) additional factors contributing to elevated velocity beyond anemia, and (iii) the presence of flow anomalies. To investigate these aspects, biological and transcranial Doppler data from pediatric and adult SCD patients were analyzed. An image-based in silico modeling approach was also developed to simulate blood flow in the internal carotid, anterior cerebral, and middle cerebral arteries of SCD patients, of different age classes, and prior to any possible stenosis. Analysis revealed that while anemia is a recognized CV risk factor, it does not fully explain elevated velocities, as no significant correlation was found in children under five. In in silico simulations, young patients reached pathological arterial intracranial velocities at physiological flow rates, whereas adults remained below risk thresholds even at high flow rates. Pathological velocities were primarily observed in distal internal carotid arteries, where stenoses often develop. High flow rates, small arterial diameters, and pronounced curvatures led to extreme velocities and complex flow, likely causing endothelial damage and promoting CV progression. These findings enhance understanding of hemodynamic mechanisms underlying SCD-related stroke risk, paving the way for improved predictive models and early interventions.

Trial Registration: ClinicalTrials.gov identifier: NCT05199766.

镰状细胞病(SCD)是儿童和年轻人中风的主要原因,主要是由于脑血管病(CV)发生在生命的第一个十年。CV的主要危险因素是颅内动脉血流速度升高,在非常年幼的儿童中导致狭窄形成。本研究解决了三个关键问题:(i) SCD患者血红蛋白水平与颅内血流速度之间的关系,(ii)除贫血外导致血流速度升高的其他因素,以及(iii)血流异常的存在。为了探讨这些方面,我们分析了儿童和成人SCD患者的生物学和经颅多普勒数据。我们还开发了一种基于图像的计算机建模方法来模拟不同年龄类别的SCD患者的颈内动脉、大脑前动脉和大脑中动脉的血流,并在任何可能的狭窄之前进行模拟。分析显示,虽然贫血是公认的心血管危险因素,但它并不能完全解释速度升高,因为在5岁以下儿童中没有发现显著的相关性。在计算机模拟中,年轻患者在生理流速下达到病理动脉颅内流速,而成人即使在高流速下仍低于风险阈值。病理速度主要在颈动脉远端观察到,那里经常发生狭窄。高流速、小动脉直径和明显的曲率导致极端的流速和复杂的血流,可能导致内皮损伤并促进心血管疾病进展。这些发现加强了对scd相关卒中风险的血液动力学机制的理解,为改进预测模型和早期干预铺平了道路。试验注册:ClinicalTrials.gov标识符:NCT05199766。
{"title":"Vascular Geometry Drives Stroke Risk in Sickle Cell Disease","authors":"Weiqiang Liu,&nbsp;Christian Kassasseya,&nbsp;Lazaros Papamanolis,&nbsp;Kim-Anh Nguyen-Peyre,&nbsp;Morgane Garreau,&nbsp;Saskia Eckert,&nbsp;Gonzalo De Luna,&nbsp;Thomas d'Humières,&nbsp;Vincent de Pierrefeu,&nbsp;Cecile Arnaud,&nbsp;Nour Bekeziz,&nbsp;Marie Pierre Gobin Metteil,&nbsp;Corentin Provost,&nbsp;Jean-Frédéric Gerbeau,&nbsp;Suzanne Verlhac,&nbsp;Pablo Bartolucci,&nbsp;Irene Vignon-Clementel","doi":"10.1002/ajh.70184","DOIUrl":"10.1002/ajh.70184","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Sickle cell disease (SCD) is the leading cause of stroke in children and young adults, primarily due to cerebral vasculopathy (CV) occurring within the first decade of life. The main risk factor for CV is elevated blood velocity in intracranial arteries, contributing to stenosis formation in very young children. This study addresses three key questions: (i) the relationship between hemoglobin levels and intracranial blood velocities in SCD patients, (ii) additional factors contributing to elevated velocity beyond anemia, and (iii) the presence of flow anomalies. To investigate these aspects, biological and transcranial Doppler data from pediatric and adult SCD patients were analyzed. An image-based in silico modeling approach was also developed to simulate blood flow in the internal carotid, anterior cerebral, and middle cerebral arteries of SCD patients, of different age classes, and prior to any possible stenosis. Analysis revealed that while anemia is a recognized CV risk factor, it does not fully explain elevated velocities, as no significant correlation was found in children under five. In in silico simulations, young patients reached pathological arterial intracranial velocities at physiological flow rates, whereas adults remained below risk thresholds even at high flow rates. Pathological velocities were primarily observed in distal internal carotid arteries, where stenoses often develop. High flow rates, small arterial diameters, and pronounced curvatures led to extreme velocities and complex flow, likely causing endothelial damage and promoting CV progression. These findings enhance understanding of hemodynamic mechanisms underlying SCD-related stroke risk, paving the way for improved predictive models and early interventions.</p>\u0000 \u0000 <p>\u0000 <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT05199766.</p>\u0000 </section>\u0000 </div>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 3","pages":"477-486"},"PeriodicalIF":9.9,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146056820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Bariatric Surgery and the Long-Term Risk for Venous Thromboembolism: A Population-Based Matched Cohort Study 减肥手术与静脉血栓栓塞长期风险之间的关系:一项基于人群的匹配队列研究。
IF 9.9 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-26 DOI: 10.1002/ajh.70186
Camille Simard, Grégoire Le Gal, Alejandro Lazo-Langner, Vicky Tagalakis, Keerat Grewal, Francis Nguyen, Tzu-Fei Wang, Deborah M. Siegal, Mehran Anvari, Aristithes G. Doumouras, Aurélien Delluc

Obesity is a known risk factor for venous thromboembolism (VTE), but the long-term effect of weight-loss interventions such as bariatric surgery on VTE risk is uncertain. We conducted a population-based matched cohort study using administrative health data from Ontario, Canada. Adults who underwent bariatric surgery between 2010 and 2016 were matched 1:1 to controls on age, sex, body mass index (BMI), and diabetes status. The primary outcome was incident VTE (deep vein thrombosis or pulmonary embolism), measured after a 3-month landmark period. Hazard ratios (HRs) were estimated using Cox models adjusted for confounders, including time-varying VTE risk factors. We included 13 502 patients who underwent bariatric surgery and 13 502 matched controls. The mean age was 45.0 years (SD 11.1), and 81.4% were women. Median follow-up was 8.4 years. VTE incidence was 0.24 per 100 person-years in the surgical group and 0.26 in the control group. Bariatric surgery was associated with a 21% reduced risk of VTE (HR 0.79; 95% CI 0.66–0.96). Risk reduction was more pronounced in men (HR 0.59; 95% CI 0.36–0.96) and in patients with BMI < 50 kg/m2. No benefit was observed in patients with BMI ≥ 50 kg/m2 or those who had sleeve gastrectomy. Bariatric surgery is associated with a long-term reduction in VTE risk, particularly among men and individuals with moderate obesity. These findings support the reversibility of obesity-related thrombosis risk and inform long-term VTE prevention strategies.

肥胖是已知的静脉血栓栓塞(VTE)的危险因素,但减肥干预措施(如减肥手术)对VTE风险的长期影响尚不确定。我们使用来自加拿大安大略省的行政卫生数据进行了一项基于人群的匹配队列研究。在2010年至2016年期间接受减肥手术的成年人在年龄、性别、体重指数(BMI)和糖尿病状况方面与对照组进行了1:1的匹配。主要终点是VTE(深静脉血栓形成或肺栓塞)的发生率,在3个月的里程碑期后测量。使用Cox模型对混杂因素(包括时变静脉血栓栓塞危险因素)进行校正,估计风险比(hr)。我们纳入了13 502名接受减肥手术的患者和13 502名匹配的对照组。平均年龄45.0岁(SD 11.1), 81.4%为女性。中位随访时间为8.4年。手术组静脉血栓栓塞发生率为0.24 / 100人年,对照组为0.26 / 100人年。减肥手术与静脉血栓栓塞风险降低21%相关(HR 0.79; 95% CI 0.66-0.96)。风险降低在男性(HR 0.59; 95% CI 0.36-0.96)和BMI为2的患者中更为明显。BMI≥50 kg/m2的患者或进行袖式胃切除术的患者未观察到任何益处。减肥手术与静脉血栓栓塞风险的长期降低有关,尤其是在男性和中度肥胖人群中。这些发现支持肥胖相关血栓形成风险的可逆性,并为长期静脉血栓形成预防策略提供信息。
{"title":"Association Between Bariatric Surgery and the Long-Term Risk for Venous Thromboembolism: A Population-Based Matched Cohort Study","authors":"Camille Simard,&nbsp;Grégoire Le Gal,&nbsp;Alejandro Lazo-Langner,&nbsp;Vicky Tagalakis,&nbsp;Keerat Grewal,&nbsp;Francis Nguyen,&nbsp;Tzu-Fei Wang,&nbsp;Deborah M. Siegal,&nbsp;Mehran Anvari,&nbsp;Aristithes G. Doumouras,&nbsp;Aurélien Delluc","doi":"10.1002/ajh.70186","DOIUrl":"10.1002/ajh.70186","url":null,"abstract":"<p>Obesity is a known risk factor for venous thromboembolism (VTE), but the long-term effect of weight-loss interventions such as bariatric surgery on VTE risk is uncertain. We conducted a population-based matched cohort study using administrative health data from Ontario, Canada. Adults who underwent bariatric surgery between 2010 and 2016 were matched 1:1 to controls on age, sex, body mass index (BMI), and diabetes status. The primary outcome was incident VTE (deep vein thrombosis or pulmonary embolism), measured after a 3-month landmark period. Hazard ratios (HRs) were estimated using Cox models adjusted for confounders, including time-varying VTE risk factors. We included 13 502 patients who underwent bariatric surgery and 13 502 matched controls. The mean age was 45.0 years (SD 11.1), and 81.4% were women. Median follow-up was 8.4 years. VTE incidence was 0.24 per 100 person-years in the surgical group and 0.26 in the control group. Bariatric surgery was associated with a 21% reduced risk of VTE (HR 0.79; 95% CI 0.66–0.96). Risk reduction was more pronounced in men (HR 0.59; 95% CI 0.36–0.96) and in patients with BMI &lt; 50 kg/m<sup>2</sup>. No benefit was observed in patients with BMI ≥ 50 kg/m<sup>2</sup> or those who had sleeve gastrectomy. Bariatric surgery is associated with a long-term reduction in VTE risk, particularly among men and individuals with moderate obesity. These findings support the reversibility of obesity-related thrombosis risk and inform long-term VTE prevention strategies.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 3","pages":"487-496"},"PeriodicalIF":9.9,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal? 重新评估新诊断的、符合移植条件的骨髓瘤患者在四联CD38单克隆抗体治疗方案下的诱导治疗时间:24周是否最佳?
IF 9.9 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-26 DOI: 10.1002/ajh.70215
Meera Mohan, Sabarinath Radhakrishnan, Carolina Schinke, Eirini Katodritou, Rafeal Fonseca
{"title":"Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal?","authors":"Meera Mohan, Sabarinath Radhakrishnan, Carolina Schinke, Eirini Katodritou, Rafeal Fonseca","doi":"10.1002/ajh.70215","DOIUrl":"https://doi.org/10.1002/ajh.70215","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial. 急性髓性白血病患者的性别、疾病特征和预后之间的关系:GIMEMA AML1310试验的性别分层分析
IF 12.8 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-24 DOI: 10.1002/ajh.70209
Lorella Maria Antonia Melillo,Valentina Arena,Alfonso Piciocchi,Anna Candoni,Valeria Calafiore,Roberto Cairoli,Paolo de Fabritiis,Gabriella Storti,Prassede Salutari,Francesco Lanza,Giovanni Martinelli,Mario Luppi,Saveria Capria,Raffaele Palmieri,Luca Maurillo,Maria Ilaria Del Principe,Maria Teresa Voso,Francesco Buccisano,Paola Fazi,Adriano Venditti
{"title":"Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial.","authors":"Lorella Maria Antonia Melillo,Valentina Arena,Alfonso Piciocchi,Anna Candoni,Valeria Calafiore,Roberto Cairoli,Paolo de Fabritiis,Gabriella Storti,Prassede Salutari,Francesco Lanza,Giovanni Martinelli,Mario Luppi,Saveria Capria,Raffaele Palmieri,Luca Maurillo,Maria Ilaria Del Principe,Maria Teresa Voso,Francesco Buccisano,Paola Fazi,Adriano Venditti","doi":"10.1002/ajh.70209","DOIUrl":"https://doi.org/10.1002/ajh.70209","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"66 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146033616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blame It on My (Arterial) Youth: How Childhood Vascular Morphology Shapes the Risk of Cerebral Vasculopathy in Sickle Cell Disease 归咎于我的(动脉)青年:儿童血管形态如何影响镰状细胞病脑血管病的风险。
IF 9.9 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-24 DOI: 10.1002/ajh.70214
Thomas Pincez
<p>In this issue of the American Journal of Hematology, Liu et al. [<span>1</span>] report how childhood artery morphology impacts blood flow and stroke risk in sickle cell disease (SCD).</p><p>Stroke is a very severe complication of SCD with a unique epidemiology for this disease. Natural history data from the landmark Cooperative Study of Sickle Cell Disease (CSSCD) showed that the risk of stroke peaks in children aged 2–5 [<span>2</span>], then decreases until a second increase after 30 [<span>2, 3</span>]. This high risk in young children is uncommon among SCD-associated organ complications and the underlying mechanisms have long been a conundrum.</p><p>The knowledge of stroke pathophysiology in SCD has much improved in the last few decades. While hemorrhagic strokes can occur [<span>3</span>], most SCD-associated strokes are ischemic. Several mechanisms can lead to cerebral ischemia, including low cardiac output or anemia exacerbation, often resulting in watershed ischemia [<span>4</span>]. However, the main cause of stroke has been identified as the progressive stenosis of large arteries (internal carotid artery [ICA] and anterior and middle cerebral arteries). This characterizes cerebral vasculopathy (CV), despite the lack of a uniform definition of this term [<span>5</span>]. One major step forward in understanding CV was the identification that arterial blood flow is accelerated before the onset of stenosis. This characteristic provided a unique opportunity for early CV screening and pre-emptive intervention. Transcranial Doppler (TCD) monitoring of arterial velocity has proven highly effective at detecting children at high risk of stroke, and it is now a cornerstone of SCD care [<span>6</span>]. The increased velocity before the development of stenosis also provided significant pathophysiological insights by showing that abnormal flow was the cause and not only the consequence of CV (although stenosis can further alter blood flow in a vicious circle).</p><p>How abnormal blood flow leads to stenosis is not fully understood. Post-mortem pathology studies revealed that stenosis was composed of intimal hyperplasia due to fibroblast and smooth muscle proliferation, internal membrane defects, and a superimposed thrombus [<span>7</span>]. This vascular lesion is likely promoted by the vascular adhesion of sickled red blood cells and activated white blood cells and platelets, resulting in endothelial dysfunction. Inflammation, hypoxia, decreased nitrite oxide bioavailability, and altered blood rheology also contribute to stenosis formation [<span>8</span>]. Several risk factors have been identified as increasing the risk of CV: hemoglobin SS or S-beta<sup>0</sup>-thalassemia type [<span>2</span>], lower hemoglobin level [<span>2</span>], high reticulocyte count [<span>9</span>], high systolic blood pressure [<span>2</span>], frequent acute chest syndrome [<span>2</span>], low fetal hemoglobin [<span>10</span>]. Several of these risk factors may
在这一期的《美国血液学杂志》上,Liu等人报道了儿童动脉形态如何影响镰状细胞病(SCD)患者的血流和卒中风险。卒中是SCD非常严重的并发症,具有独特的流行病学特征。具有里程碑意义的镰状细胞病合作研究(CSSCD)的自然历史数据显示,中风的风险在2 - 5岁儿童中达到峰值,然后下降,直到30岁后再次增加[2,3]。这种高风险在幼儿scd相关器官并发症中并不常见,其潜在机制长期以来一直是一个难题。在过去的几十年里,脑卒中病理生理学的知识有了很大的提高。出血性中风可以发生,但大多数scd相关中风是缺血性的。多种机制可导致脑缺血,包括低心输出量或贫血加重,通常导致分水岭缺血[4]。然而,中风的主要原因已被确定为大动脉(颈内动脉[ICA]和大脑前动脉和中动脉)的进行性狭窄。这是脑血管病(CV)的特征,尽管[5]这个术语缺乏统一的定义。了解心血管疾病的一个重要步骤是确定动脉血流在狭窄发生前加速。这一特点为早期CV筛查和先发制人的干预提供了独特的机会。经颅多普勒(TCD)动脉流速监测已被证明在检测中风高风险儿童方面非常有效,现在它是SCD护理的基石。在狭窄发生之前流速的增加也提供了重要的病理生理学见解,表明异常血流是CV的原因,而不仅仅是结果(尽管狭窄可以进一步改变血流形成恶性循环)。异常血流是如何导致狭窄的尚不完全清楚。死后病理研究显示狭窄由成纤维细胞和平滑肌增生引起的内膜增生、内膜缺陷和叠加血栓组成。这种血管病变可能是由镰状红细胞和活化的白细胞和血小板的血管粘附促进的,导致内皮功能障碍。炎症、缺氧、亚硝酸盐氧化物生物利用度降低和血液流变学改变也有助于狭窄形成[8]。几个危险因素已被确定为增加CV的风险:血红蛋白SS或s - β -地中海贫血型[2],血红蛋白水平较低[2],高网状红细胞计数[9],高收缩压[2],频繁急性胸综合征[2],低胎儿血红蛋白[10]。其中一些危险因素可能与心排血量增加有关,导致颅内流速加快。一些基因的遗传变异也可能影响中风的风险。然而,由于病理生理机制和危险因素不依赖于年龄,它们不能解释为什么幼儿携带CV的风险增加。关于孩子,有一个证据:他们正在长大。他们的大脑也一样,需要支持。幼童脑血流量大,这是由于脑部生长的代谢需要所致。为了满足必要的脑内血流量,心输出量增加,导致动脉流速提高。目前尚不清楚这种机制是否可以完全解释SCD中CV的年龄相关模式。Liu等人认为另一个因素可能参与其中:年轻大脑动脉的独特几何形状。为了研究动脉几何形状的影响,作者将不同年龄组SCD患者的TCD和磁共振血管造影(MRA)数据结合数学建模和血流模拟。他们首先证实血红蛋白与TCD的时间平均最大流速(TAMV)有关,TCD是衡量大脑动脉流速的金标准。较高的TAMV与较低的血红蛋白水平相关,可能是由于心输出量代偿性增加。这与低血红蛋白水平与中风的高风险相一致。然而,在5岁以下的儿童中,ICA的关系不太明显,大脑前动脉和中动脉甚至不存在这种关系。这表明幼儿患CA的高风险不能完全用心输出量增加来解释。为了更好地了解影响血流的因素,作者使用MRA研究了15名患者的脑动脉形态。他们发现,与成人相比,5岁以下儿童的动脉有几个特点:ICA虹吸管的直径变小,角度更明显,椭圆度更小(即ICA虹吸管更弯曲,更不平坦)。 然后,他们通过模拟各种血流(反映心输出量),使用MRA重建来研究这种形态对TAMV的影响。他们发现,对于给定的动脉血流速率,不同年龄组动脉内的血流表现不同。在幼儿中,即使进入血流量与基线心输出量的生理值相对应,也经常达到高(病理性)TAMV。在年龄较大的儿童中,只有在高进入血流量的情况下才能达到高TAMV,模拟心输出量的短暂增加。在成人中从未达到高TAMV。这种高TAMV与流动的复杂性有关,有时被称为湍流。这表明较高的速度是由于形态约束引起的流动干扰造成的。在ICA远端和ICA虹吸管中发现了最高的速度,这是一个由于其弯曲而有利于复杂流动的区域。总的来说,这些数据提出了幼儿scd相关CV风险增加的机制。这个年龄段的动脉更窄、角度更大,形成了复杂的湍流,形成了高速区域。这就像河流较窄弯曲部分的急流。最终,复杂的流动将导致狭窄。这种现象随着年龄的增长而逐渐减少,因为动脉的解剖结构变得更大,更少弯曲,更椭圆,这降低了血流的复杂性。这些结果也解释了为什么加速速度经常是单边的。由于动脉的形态通常是不对称的,因此对两侧血流的影响是不同的。这一新的机制可以与其他因素相结合,提出SCD中CV的责任模型。CV的发展是由ICA和脑动脉的高血流量驱动的。这种血流量增加是由于幼儿动脉形态和其他因素,如总血红蛋白和胎儿血红蛋白水平。最后,高血流量对心血管发展的影响是由炎症和缺氧调节的。这些结果目前还没有直接的临床意义。很难设想对形态因素的作用。然而,有人可能会推测,这些知识可以更好地预测风险。基于核磁共振成像的重建可以预先估计高速度的可能性,并相应地调整治疗强度。研究一个非常相关的应用是基于核磁共振成像的重建在决定是否停止慢性输血治疗中的有用性。目前,慢性输血治疗是未接受造血干细胞移植的病理性TAMV患者的标准治疗方法。然而,一旦慢性输血项目开始,目前还没有明确的工具来帮助确定哪些患者可以安全地停止输血。确定停止输血后血流量增加可能导致的预期TAMV,有助于确定病理性TAMV复发风险高或低的患者。这可能会导致对SCD患者进行更个性化的管理,这是我们尚未达到的目标。数据共享不适用于本文,因为在本研究中没有生成或分析数据集。
{"title":"Blame It on My (Arterial) Youth: How Childhood Vascular Morphology Shapes the Risk of Cerebral Vasculopathy in Sickle Cell Disease","authors":"Thomas Pincez","doi":"10.1002/ajh.70214","DOIUrl":"10.1002/ajh.70214","url":null,"abstract":"&lt;p&gt;In this issue of the American Journal of Hematology, Liu et al. [&lt;span&gt;1&lt;/span&gt;] report how childhood artery morphology impacts blood flow and stroke risk in sickle cell disease (SCD).&lt;/p&gt;&lt;p&gt;Stroke is a very severe complication of SCD with a unique epidemiology for this disease. Natural history data from the landmark Cooperative Study of Sickle Cell Disease (CSSCD) showed that the risk of stroke peaks in children aged 2–5 [&lt;span&gt;2&lt;/span&gt;], then decreases until a second increase after 30 [&lt;span&gt;2, 3&lt;/span&gt;]. This high risk in young children is uncommon among SCD-associated organ complications and the underlying mechanisms have long been a conundrum.&lt;/p&gt;&lt;p&gt;The knowledge of stroke pathophysiology in SCD has much improved in the last few decades. While hemorrhagic strokes can occur [&lt;span&gt;3&lt;/span&gt;], most SCD-associated strokes are ischemic. Several mechanisms can lead to cerebral ischemia, including low cardiac output or anemia exacerbation, often resulting in watershed ischemia [&lt;span&gt;4&lt;/span&gt;]. However, the main cause of stroke has been identified as the progressive stenosis of large arteries (internal carotid artery [ICA] and anterior and middle cerebral arteries). This characterizes cerebral vasculopathy (CV), despite the lack of a uniform definition of this term [&lt;span&gt;5&lt;/span&gt;]. One major step forward in understanding CV was the identification that arterial blood flow is accelerated before the onset of stenosis. This characteristic provided a unique opportunity for early CV screening and pre-emptive intervention. Transcranial Doppler (TCD) monitoring of arterial velocity has proven highly effective at detecting children at high risk of stroke, and it is now a cornerstone of SCD care [&lt;span&gt;6&lt;/span&gt;]. The increased velocity before the development of stenosis also provided significant pathophysiological insights by showing that abnormal flow was the cause and not only the consequence of CV (although stenosis can further alter blood flow in a vicious circle).&lt;/p&gt;&lt;p&gt;How abnormal blood flow leads to stenosis is not fully understood. Post-mortem pathology studies revealed that stenosis was composed of intimal hyperplasia due to fibroblast and smooth muscle proliferation, internal membrane defects, and a superimposed thrombus [&lt;span&gt;7&lt;/span&gt;]. This vascular lesion is likely promoted by the vascular adhesion of sickled red blood cells and activated white blood cells and platelets, resulting in endothelial dysfunction. Inflammation, hypoxia, decreased nitrite oxide bioavailability, and altered blood rheology also contribute to stenosis formation [&lt;span&gt;8&lt;/span&gt;]. Several risk factors have been identified as increasing the risk of CV: hemoglobin SS or S-beta&lt;sup&gt;0&lt;/sup&gt;-thalassemia type [&lt;span&gt;2&lt;/span&gt;], lower hemoglobin level [&lt;span&gt;2&lt;/span&gt;], high reticulocyte count [&lt;span&gt;9&lt;/span&gt;], high systolic blood pressure [&lt;span&gt;2&lt;/span&gt;], frequent acute chest syndrome [&lt;span&gt;2&lt;/span&gt;], low fetal hemoglobin [&lt;span&gt;10&lt;/span&gt;]. Several of these risk factors may","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 3","pages":"415-417"},"PeriodicalIF":9.9,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146033613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autosomal Dominant Erythrocytosis Caused by Non-Renal Erythropoietin (EPO) Due to EPO c.-136 G>A Germline Mutation. 由非肾性促红细胞生成素(EPO)引起的常染色体显性红细胞增多症(由EPO c.- 136g>a种系突变引起)
IF 12.8 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-23 DOI: 10.1002/ajh.70208
Lucie Lanikova,Dusan Hrckulak,Veronika Zimolova,Felipe R Lorenzo,Jihyun Song,Katerina Vecerkova,Olga Babosova,Linda Berkova,Vladimir Korinek,Steve Elliott,Josef T Prchal
We previously reported a five-generation kindred with autosomal dominant erythrocytosis associated with a novel germline promoter variant in the erythropoietin (EPO) gene (EPO c.-136 G>A). This mutation creates a new hypoxia response element (HRE) consensus sequence on the reverse strand suggesting a gain of function mutation. CRISPR/Cas9-edited Hep3B cells harboring the c.-136 G>A variant had increased EPO mRNA and protein expression under both normoxic and hypoxic conditions compared to wild-type cells; functional assays confirmed the activity of the c.-136 G>A variant-induced EPO. Isoelectric focusing analyses of patient urine and plasma showed a more basic EPO isoform pattern, consistent with the reduced sulfated N-glycan contribution, suggesting decreased renal and increased non-renal expression. Luciferase reporter assays confirmed increased transcriptional activation of the mutant promoter. However, chromatin immunoprecipitation did not verify direct hypoxia-inducible factor (HIF)-1/2 binding, suggesting the possible involvement of alternative regulatory elements. These findings support a model in which the EPO c.-136 G>A promoter variant introduces a new HRE that overrides the normal kidney expression resulting in persistent or ectopic non-renal EPO production postnatally. This study expands the spectrum of molecular mechanisms underlying hereditary erythrocytosis and provides novel mechanistic insights into EPO regulation, including its tissue-specific expression.
我们之前报道了一个常染色体显性红细胞增多症的五代亲缘关系,该亲缘关系与促红细胞生成素(EPO)基因(EPO c.-136 G> a)的一种新的种系启动子变异有关。该突变在反向链上产生了一个新的缺氧反应元件(HRE)共识序列,表明功能突变的增加。与野生型细胞相比,CRISPR/ cas9编辑的含有c -136 G>A变体的Hep3B细胞在常氧和缺氧条件下都增加了EPO mRNA和蛋白的表达;功能分析证实c - 136g>a变异体诱导的EPO具有活性。患者尿液和血浆等电聚焦分析显示更基本的EPO异构体模式,与巯基n-聚糖的减少一致,表明肾脏表达减少,非肾脏表达增加。荧光素酶报告基因检测证实突变启动子的转录激活增加。然而,染色质免疫沉淀未证实直接缺氧诱导因子(HIF)-1/2结合,提示可能涉及其他调节元件。这些发现支持了EPO c -136 G bbbba启动子变异引入新的HRE的模型,该HRE覆盖正常肾脏表达,导致出生后持续或异位的非肾脏EPO产生。这项研究扩展了遗传性红细胞增多症的分子机制,并为EPO调控提供了新的机制见解,包括其组织特异性表达。
{"title":"Autosomal Dominant Erythrocytosis Caused by Non-Renal Erythropoietin (EPO) Due to EPO c.-136 G>A Germline Mutation.","authors":"Lucie Lanikova,Dusan Hrckulak,Veronika Zimolova,Felipe R Lorenzo,Jihyun Song,Katerina Vecerkova,Olga Babosova,Linda Berkova,Vladimir Korinek,Steve Elliott,Josef T Prchal","doi":"10.1002/ajh.70208","DOIUrl":"https://doi.org/10.1002/ajh.70208","url":null,"abstract":"We previously reported a five-generation kindred with autosomal dominant erythrocytosis associated with a novel germline promoter variant in the erythropoietin (EPO) gene (EPO c.-136 G>A). This mutation creates a new hypoxia response element (HRE) consensus sequence on the reverse strand suggesting a gain of function mutation. CRISPR/Cas9-edited Hep3B cells harboring the c.-136 G>A variant had increased EPO mRNA and protein expression under both normoxic and hypoxic conditions compared to wild-type cells; functional assays confirmed the activity of the c.-136 G>A variant-induced EPO. Isoelectric focusing analyses of patient urine and plasma showed a more basic EPO isoform pattern, consistent with the reduced sulfated N-glycan contribution, suggesting decreased renal and increased non-renal expression. Luciferase reporter assays confirmed increased transcriptional activation of the mutant promoter. However, chromatin immunoprecipitation did not verify direct hypoxia-inducible factor (HIF)-1/2 binding, suggesting the possible involvement of alternative regulatory elements. These findings support a model in which the EPO c.-136 G>A promoter variant introduces a new HRE that overrides the normal kidney expression resulting in persistent or ectopic non-renal EPO production postnatally. This study expands the spectrum of molecular mechanisms underlying hereditary erythrocytosis and provides novel mechanistic insights into EPO regulation, including its tissue-specific expression.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"58 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146021677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are Current Exposure Models Sufficient to Link Pollution to MDS Progression?: The Impact of Overlooked Social and Environmental Confounders. 当前的暴露模型是否足以将污染与MDS进展联系起来?:被忽视的社会和环境混杂因素的影响。
IF 12.8 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-21 DOI: 10.1002/ajh.70211
Howard Lopes Ribeiro Junior,Jonas Nogueira Ferreira Maciel Gusmão,João Vitor Caetano Goes,Danielle Calheiros Campelo Maia
{"title":"Are Current Exposure Models Sufficient to Link Pollution to MDS Progression?: The Impact of Overlooked Social and Environmental Confounders.","authors":"Howard Lopes Ribeiro Junior,Jonas Nogueira Ferreira Maciel Gusmão,João Vitor Caetano Goes,Danielle Calheiros Campelo Maia","doi":"10.1002/ajh.70211","DOIUrl":"https://doi.org/10.1002/ajh.70211","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"36 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146015349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study 突变景观和负担对低风险骨髓增生异常综合征(LR-MDS)患者红细胞输血反应的影响
IF 9.9 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-19 DOI: 10.1002/ajh.70171
Rami S. Komrokji, Sheida Hayati, Manuel Ugidos, Guillermo Garcia-Manero, Matteo Giovanni Della Porta, Amer M. Zeidan, Valeria Santini, Uwe Platzbecker, Anita K. Gandhi, Rajasekhar N. V. S. Suragani

The COMMANDS trial established luspatercept as a first-line treatment for anemia in transfusion-dependent lower-risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS trial. Of 350 evaluable patients, 238 (68.0%) had MDS with multiple lineage dysplasia and ring sideroblasts (RS) according to World Health Organization 2016 criteria, and 320 (91.4%) had somatic mutations in ≥ 1 gene (median, 2) with median variant allele frequencies (VAF) of 2%–59%. Mutation profiles were similar in the treatment groups. Luspatercept had superior responses versus epoetin alfa across multiple mutations (risk difference; RD, [95% confidence interval; CI] 0.25 [0.15–0.35]), including in SF3B1-mutated (0.38 [0.25–0.50]) and SF3B1 wild-type (0.09 [−0.11 to 0.30]). Luspatercept demonstrated superior responses in patients with VAF ≥ 10% (random effect, 0.36 [95% CI, 0.28–0.44]), and in those with 1 (63% vs. 40%; p = 0.040), 2 (70% vs. 27%; p < 0.001), and 3 (72% vs. 40%; p = 0.018) mutations, and across the low (75% vs. 38%), moderate low (61% vs. 38%), moderate high (44% vs. 21%), and high (36% vs. 24%) Molecular International Prognostic Scoring System risk groups (summary effect RD, 0.26 [95% CI, 0.14–0.37]). Across most mutations luspatercept responses were superior (random effect, 0.34 [95% CI, 0.24–0.44]) in patients with RS but were similar between treatments in RS-negative patients. Luspatercept represents an effective treatment option in various mutational backgrounds in LR MDS.

Trial Registration: ClinicalTrials.gov Identifier: NCT03682536.

COMMANDS试验确定luspatercept作为输血依赖性低风险(LR)骨髓增生异常综合征(MDS)贫血的一线治疗药物。在此,我们报告了在COMMANDS试验中使用luspaterceept或eppoetin治疗的患者的基于体细胞突变谱和疾病风险的红细胞(RBC)输血反应分析。在350名可评估的患者中,根据世界卫生组织2016年的标准,238名(68.0%)患有MDS伴多谱系发育不良和环状铁母细胞(RS), 320名(91.4%)患有≥1个基因的体细胞突变(中位数,2),中位变异等位基因频率(VAF)为2%-59%。治疗组的突变谱相似。与epoetin α相比,Luspatercept在多种突变(风险差异;RD,[95%置信区间;CI] 0.25[0.15-0.35])中具有更好的应答,包括SF3B1突变(0.38[0.25-0.50])和SF3B1野生型(0.09[-0.11至0.30])。Luspatercept在VAF≥10%的患者(随机效应,0.36 [95% CI, 0.28-0.44])、1(63%对40%,p = 0.040)、2(70%对27%,p < 0.001)和3(72%对40%,p = 0.018)突变患者以及低(75%对38%)、中低(61%对38%)、中高(44%对21%)和高(36%对24%)分子国际预后评分系统风险组(总效应RD, 0.26 [95% CI, 0.14-0.37])中表现出优越的疗效。在大多数突变中,RS患者的luspatercept反应更好(随机效应,0.34 [95% CI, 0.24-0.44]),但RS阴性患者的治疗效果相似。Luspatercept在LR MDS的各种突变背景下是一种有效的治疗选择。试验注册:ClinicalTrials.gov标识符:NCT03682536。
{"title":"Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study","authors":"Rami S. Komrokji,&nbsp;Sheida Hayati,&nbsp;Manuel Ugidos,&nbsp;Guillermo Garcia-Manero,&nbsp;Matteo Giovanni Della Porta,&nbsp;Amer M. Zeidan,&nbsp;Valeria Santini,&nbsp;Uwe Platzbecker,&nbsp;Anita K. Gandhi,&nbsp;Rajasekhar N. V. S. Suragani","doi":"10.1002/ajh.70171","DOIUrl":"10.1002/ajh.70171","url":null,"abstract":"<p>The COMMANDS trial established luspatercept as a first-line treatment for anemia in transfusion-dependent lower-risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS trial. Of 350 evaluable patients, 238 (68.0%) had MDS with multiple lineage dysplasia and ring sideroblasts (RS) according to World Health Organization 2016 criteria, and 320 (91.4%) had somatic mutations in ≥ 1 gene (median, 2) with median variant allele frequencies (VAF) of 2%–59%. Mutation profiles were similar in the treatment groups. Luspatercept had superior responses versus epoetin alfa across multiple mutations (risk difference; RD, [95% confidence interval; CI] 0.25 [0.15–0.35]), including in <i>SF3B1</i>-mutated (0.38 [0.25–0.50]) and <i>SF3B1</i> wild-type (0.09 [−0.11 to 0.30]). Luspatercept demonstrated superior responses in patients with VAF ≥ 10% (random effect, 0.36 [95% CI, 0.28–0.44]), and in those with 1 (63% vs. 40%; <i>p</i> = 0.040), 2 (70% vs. 27%; <i>p</i> &lt; 0.001), and 3 (72% vs. 40%; <i>p</i> = 0.018) mutations, and across the low (75% vs. 38%), moderate low (61% vs. 38%), moderate high (44% vs. 21%), and high (36% vs. 24%) Molecular International Prognostic Scoring System risk groups (summary effect RD, 0.26 [95% CI, 0.14–0.37]). Across most mutations luspatercept responses were superior (random effect, 0.34 [95% CI, 0.24–0.44]) in patients with RS but were similar between treatments in RS-negative patients. Luspatercept represents an effective treatment option in various mutational backgrounds in LR MDS.</p><p>\u0000 <b>Trial Registration:</b> ClinicalTrials.gov Identifier: NCT03682536.</p>","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"101 3","pages":"427-438"},"PeriodicalIF":9.9,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.70171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adult-Onset β-Thalassemia Major as Acquired Imprinting Disorder. 成人发病的β-地中海贫血为获得性印记障碍。
IF 12.8 1区 医学 Q1 HEMATOLOGY Pub Date : 2026-01-16 DOI: 10.1002/ajh.70177
Emilia D'Angelo,Giorgia Mandrile,Nicolò Tesio,Francesco Cecere,Teresa Ceglie,Rosa Maria De Maria,Simona Mellone,Mara Giordano,Neha Sanjay Kargutar,Flavia Cerrato,Andrea Riccio,Giovanni Battista Ferrero
{"title":"Adult-Onset β-Thalassemia Major as Acquired Imprinting Disorder.","authors":"Emilia D'Angelo,Giorgia Mandrile,Nicolò Tesio,Francesco Cecere,Teresa Ceglie,Rosa Maria De Maria,Simona Mellone,Mara Giordano,Neha Sanjay Kargutar,Flavia Cerrato,Andrea Riccio,Giovanni Battista Ferrero","doi":"10.1002/ajh.70177","DOIUrl":"https://doi.org/10.1002/ajh.70177","url":null,"abstract":"","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":"35 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American Journal of Hematology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1